Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43850   clinical trials with a EudraCT protocol, of which   7282   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2018-004354-21
    Sponsor's Protocol Code Number:207499
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2020-10-21
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2018-004354-21
    A.3Full title of the trial
    A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone (B-Pd) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) in Participants with Relapsed/Refractory Multiple Myeloma (DREAMM 8)
    Studio di fase III, multicentrico, in aperto, randomizzato volto a valutare l’efficacia e la sicurezza di belantamab mafodotin in combinazione con pomalidomide e desametasone (B Pd) rispetto a pomalidomide, bortezomib e desametasone (PVd) in partecipanti affetti da mieloma multiplo recidivante/refrattario (DREAMM 8)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study of a combination of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) compared to Bortezomib with Pomalidomide and Dexamethasone (PVd) in Participants with Relapsed/Refractory Multiple Myeloma
    Studio con belantamab mafodotin in combinazione con pomalidomide e desametasone (B Pd) rispetto a pomalidomide, bortezomib e desametasone (PVd) in partecipanti affetti da mieloma multiplo recidivante/refrattario
    A.3.2Name or abbreviated title of the trial where available
    DREAMM-8 (ACRONYM)
    DREAMM-8 (ACRONIMO)
    A.4.1Sponsor's protocol code number207499
    A.5.4Other Identifiers
    Name:Study acronym DREAMM-8Number:Study acronym DREAMM-8
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorGLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
    B.1.3.4CountryUnited Kingdom
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportGlaxoSmithKline Research & Development Limited
    B.4.2CountryUnited Kingdom
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationGlaxoSmithKline Research & Development Ltd
    B.5.2Functional name of contact pointGSK Clinical Support Help Desk
    B.5.3 Address:
    B.5.3.1Street Address980 Great West Road
    B.5.3.2Town/ cityBrentford, Middlesex
    B.5.3.3Post codeTW8 9GS
    B.5.3.4CountryUnited Kingdom
    B.5.4Telephone number08007839733
    B.5.6E-mailGSKClinicalSupportHD@gsk.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/17/1925
    D.3 Description of the IMP
    D.3.1Product nameBelantamab Mafodotin
    D.3.2Product code [GSK2857916]
    D.3.4Pharmaceutical form Powder for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNbelantamab mafodotin
    D.3.9.2Current sponsor codeGSK2857916
    D.3.9.4EV Substance CodeSUB130430
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeBelantamab Mafodotin is a humanised afucosylated, maleimidocaproyl monomethyl auristatin phenylalanine (mcMMAF) conjugated IgG1 antibody.
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Imnovid
    D.2.1.1.2Name of the Marketing Authorisation holderCelgene Europe B.V
    D.2.1.2Country which granted the Marketing AuthorisationGermany
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/09/672
    D.3 Description of the IMP
    D.3.1Product namepomalidomide
    D.3.2Product code [pomalidomide]
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNpomalidomide
    D.3.9.1CAS number 19171-19-8
    D.3.9.2Current sponsor codepomalidomide
    D.3.9.4EV Substance CodeSUB33379
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Dexamethasone Tablets BP 2.0mg
    D.2.1.1.2Name of the Marketing Authorisation holderAspen Pharma Trading Limited
    D.2.1.2Country which granted the Marketing AuthorisationIreland
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameDEXAMETHASONE
    D.3.2Product code [DEXAMETHASONE]
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDESAMETASONE
    D.3.9.2Current sponsor codeDEXAMETHASONE
    D.3.9.4EV Substance CodeSUB07017MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number2
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name VELCADE 3,5 mg
    D.2.1.1.2Name of the Marketing Authorisation holderJANSSEN-CILAG INTERNATIONAL NV
    D.2.1.2Country which granted the Marketing AuthorisationBelgium
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameBortezomib
    D.3.2Product code [Bortezomib]
    D.3.4Pharmaceutical form Powder for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNBORTEZOMIB
    D.3.9.1CAS number 179324-69-7
    D.3.9.2Current sponsor codebortezomib
    D.3.9.4EV Substance CodeSUB20020
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number3500
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 5
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name imnovid
    D.2.1.1.2Name of the Marketing Authorisation holderCelgene Europe B.V
    D.2.1.2Country which granted the Marketing AuthorisationGermany
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/09/672
    D.3 Description of the IMP
    D.3.1Product namepomalidomide
    D.3.2Product code [pomalidomide]
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNpomalidomide
    D.3.9.1CAS number 19171-19-8
    D.3.9.2Current sponsor codepomalidomide
    D.3.9.4EV Substance CodeSUB33379
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number4
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 6
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Dexamethasone 2mg Tablets
    D.2.1.1.2Name of the Marketing Authorisation holderTEVA UK Limited
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameDexamethasone
    D.3.2Product code [Dexamethasone]
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDESAMETASONE
    D.3.9.2Current sponsor codeDexamethasone
    D.3.9.4EV Substance CodeSUB07017MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number2
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 7
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Dexamethason 8 mg GALEN®
    D.2.1.1.2Name of the Marketing Authorisation holderGALENpharma GmbH
    D.2.1.2Country which granted the Marketing AuthorisationGermany
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameDexamethasone
    D.3.2Product code [Dexamethasone]
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDESAMETASONE
    D.3.9.2Current sponsor codeDexamethasone
    D.3.9.4EV Substance CodeSUB07017MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number8
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 8
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Imnovid
    D.2.1.1.2Name of the Marketing Authorisation holderCelgene Europe B.V
    D.2.1.2Country which granted the Marketing AuthorisationGermany
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/09/672
    D.3 Description of the IMP
    D.3.1Product namepomalidomide
    D.3.2Product code [pomalidomide]
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNpomalidomide
    D.3.9.1CAS number 19171-19-8
    D.3.9.2Current sponsor codepomalidomide
    D.3.9.4EV Substance CodeSUB33379
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number3
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 9
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Dexamethasone 8 mg JENAPHARM®
    D.2.1.1.2Name of the Marketing Authorisation holdermibe GmbH Arzneimittel
    D.2.1.2Country which granted the Marketing AuthorisationGermany
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameDexamethasone
    D.3.2Product code [Dexamethasone]
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDESAMETASONE
    D.3.9.2Current sponsor codeDexamethasone
    D.3.9.4EV Substance CodeSUB07017MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number8
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Relapsed/Refractory Multiple Myeloma
    Relapsed/Refractory Multiple Myeloma
    E.1.1.1Medical condition in easily understood language
    Relapsed / Refectory Multiple Myeloma
    Relapsed / Refectory Multiple Myeloma
    E.1.1.2Therapeutic area Diseases [C] - Blood and lymphatic diseases [C15]
    MedDRA Classification
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To compare the efficacy of belantamab mafodotin in combination with pomalidomide and dexamethasone (BPd) with that of pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed/refractory multiple myeloma (RRMM)
    Confrontare l’efficacia di belantamab mafodotin in combinazione con pomalidomide e desametasone (B-Pd) e quella di pomalidomide, bortezomib e desametasone (PVd) nei partecipanti affetti da MMRR
    E.2.2Secondary objectives of the trial
    To further compare the efficacy of belantamab mafodotin in combination with pomalidomide and dexamethasone (B-Pd) with that of pomalidomide, bortezomib and dexamethasone (PVd) in participants with RRMM
    To further assess the efficacy of B-Pd in terms of other efficacy outcomes in participants with RRMM
    To evaluate the safety and tolerability of belantamab mafodotin when administered in combination with pomalidomide and dexamethasone
    To document exposure of belantamab mafodotin when administered in combination with pomalidomide and dexamethasone
    To evaluate the PK of pomalidomide in combination with belantamab mafodotin and dexamethasone, in a subset of participants
    To assess anti-drug antibodies against belantamab mafodotin
    To evaluate the safety and tolerability of belantamab mafodotin based on selfreported symptomatic AEs when administered in combination with pomalidomide and dexamethasone
    To evaluate and compare changes in symptoms and health-related quality of life
    Confrontare ulteriormente l’efficacia di belantamab mafodotin in combinazione con pomalidomide e desametasone (B-Pd) e quella di pomalidomide, bortezomib e desametasone (PVd) nei partecipanti affetti da MMRR
    Valutare ulteriormente l’efficacia di belantamab mafodotin in combinazione con pomalidomide e desametasone in termini di altri esiti di efficacia nei partecipanti affetti da MMRR
    Valutare la sicurezza e la tollerabilità di belantamab mafodotin somministrato in combinazione con pomalidomide e desametasone
    Valutare la farmacocinetica di pomalidomide in combinazione con belantamab mafodotin e desametasone in un sottogruppo di partecipanti
    Valutare gli anticorpi anti-farmaco (ADA) contro belantamab mafodotin
    Valutare la sicurezza e la tollerabilità di belantamab mafodotin, sulla base degli effetti avversi sintomatici autosegnalati, somministrato in combinazione con pomalidomide e desametasone
    Valutare e confrontare i cambiamenti nei sintomi e la qualità della vita correlata alla salute
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Participants are eligible to be included in the study only if all of the following criteria are met:
    1. Capable of giving signed informed consent as described in Section 10.1.3, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
    2. Male or female, 18 years or older (at the time consent is obtained).
    3. Have a confirmed diagnosis of multiple myeloma as defined by the IMWG criteria [Rajkumar, 2016].
    4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 (Section 10.6).
    5. Have been previously treated with at least 1 prior line of MM therapy including a lenalidomide-containing regimen (lenalidomide must have been administered for at least 2 consecutive cycles) and must have documented disease progression during or after their most recent therapy.
    Note: Participants intolerant or refractory to bortezomib at 1.3 mg/m2 dose twice weekly dosing schedule are not eligible.
    6. Must have at least ONE aspect of measurable disease, defined as one the following:
    a. Urine M-protein excretion =200 mg/24 h, or
    b. Serum M-protein concentration =0.5 g/dL (=5.0 g/L), or
    c. Serum free light chain (FLC) assay: involved FLC level =10 mg/dL (=100 mg/L) and an abnormal serum free light chain ratio (<0.26 or >1.65) only if patient has no measurable urine or serum M spike.
    7. Have undergone autologous stem cell transplant (SCT) or are considered transplant ineligible. Participants with a history of autologous SCT are eligible for study participation provided the following eligibility criteria are met:
    a. Autologous SCT was >100 days prior to the first dose of study medication
    b. No active bacterial, viral, or fungal infection(s) present
    8. All prior treatment-related toxicities (defined by National Cancer Institute Common Toxicity Criteria for Adverse Events [NCI-CTCAE] v5.0) must be =Grade 1 at the time of enrolment, except for alopecia.
    9. Adequate organ system functions as defined by the laboratory assessments listed in the protocol
    Il soggetto è in grado di fornire un consenso informato firmato, come descritto alla Sezione 10.1.3, che includa la conformità ai requisiti e alle restrizioni elencati nel modulo di consenso informato (ICF) e nel presente protocollo.
    2. Sesso maschile o femminile e almeno 18 anni di età (nel momento in cui viene ottenuto il consenso).
    3. Avere una diagnosi confermata di mieloma multiplo, come definito dai criteri dell’IMWG [Rajkumar, 2016].
    4.Stato prestazionale secondo il Gruppo cooperativo orientale di oncologia (ECOG) di 0-2
    5. Essere stati precedentemente trattati con almeno 1 precedente linea di terapia per il MM, tra cui un regime terapeutico contenente lenalidomide (lenalidomide deve essere stato somministrato per almeno 2 cicli consecutivi) e devono presentare progressione della malattia documentata durante o dopo la terapia più recente.
    7. Nota: non sono idonei i partecipanti intolleranti o refrattari allo schema di somministrazione che include bortezomib alla dose di 1,3 mg/m2 due volte a settimana.
    8. Devono presentare almeno UN aspetto di malattia misurabile definita come segue:
    a. Escrezione di proteina M nelle urine =200 mg/24 h, oppure
    b. Concentrazione di proteina M nel siero =0,5 g/dl (=5,0 g/l) oppure
    c. Esame per le FLC: livello di FLC coinvolte =10 mg/dl (=100 mg/l) e rapporto anomalo della catena leggera libera nel siero (<0,26 o >1,65) solo se il paziente non ha un picco di M urinario o sierico misurabile.
    Sono stati sopposti a trapianto autologo di cellule staminali (SCT) o sono considerati non idonei al trapianto. I partecipanti con un’anamnesi di SCT autologo sono idonei per la partecipazione allo studio a condizione che i seguenti criteri di idoneità siano soddisfatti:
    a. Il trapianto autologo di cellule staminali è stato eseguito >100 giorni prima della prima dose del farmaco dello studio
    b. Nessuna infezione batterica, virale o micotica attiva presente
    10. Tutte le precedenti tossicità correlate al trattamento (definite in base ai Criteri comuni di tossicità per gli eventi avversi [NCI-CTCAE] v.5.0) devono essere di Grado =1 al momento dell’arruolamento, ad eccezione dell’alopecia.
    11.Funzioni del sistema d’organo adeguate, come definito dalle valutazioni di laboratorio
    E.4Principal exclusion criteria
    A participant will not be eligible for inclusion in this study if any of the following criteria are met:
    1. Active plasma cell leukemia at the time of screening. Symptomatic amyloidosis, active POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma proliferative disorder, and skin changes).
    2. Participants after prior allogeneic SCT.
    3. Systemic anti-myeloma therapy (including chemotherapy and systemic steroids) or use of an investigational drug within 14 days or five half-lives (whichever is shorter) preceding the first dose of study drug; Prior treatment with a monoclonal antibody drug within 30 days of receiving the first dose of study drugs.
    4. Plasmapheresis within 7 days prior to the first dose of study drug.
    5. Received prior treatment with or intolerant to pomalidomide.
    6. Received prior BCMA targeted therapy.
    7. Intolerant to bortezomib or refractory to bortezomib (i.e., participant experienced progressive disease during treatment, or within 60 days of completing treatment, with a bortezomib-containing regimen of 1.3 mg/m2 twice weekly).
    8. Evidence of cardiovascular risk including any of the following:
    a. Evidence of current clinically significant untreated arrhythmias, including clinically significant ECG abnormalities including 2nd degree (Mobitz Type II) or 3rd degree atrioventricular (AV) block.
    b. History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within 3 months of Screening.
    c. Class III or IV heart failure as defined by the New York Heart Association functional classification system (Section 10.8)
    d. Uncontrolled hypertension.
    9. Any major surgery within the last 4 weeks.
    10. Previous or concurrent invasive malignancy other than multiple myeloma, except:
    • The disease must be considered medically stable for at least 2 years; or
    • The participant must not be receiving active therapy, other than hormonal therapy for this disease.
    11. Known immediate or delayed hypersensitivity reaction or idiosyncratic reaction to belantamab mafodotin or drugs chemically related to belantamab mafodotin, or any of the components of the study treatment.
    12. Evidence of active mucosal or internal bleeding.
    13. Cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric varices, persistent jaundice.
    14. Active infection requiring treatment.
    15. Known human immunodeficiency virus (HIV) infection.
    16. Presence of hepatitis B surface antigen (HbsAg), or hepatitis B core antibody (HbcAb) at Screening or within 3 months prior to first dose of study treatment).
    17. Positive hepatitis C antibody test result or positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study treatment.
    18. Intolerance or contraindications to anti-viral prophylaxis.
    19. Presence of active renal conditions (e.g. infection, severe renal impairment requiring dialysis or any other condition that could affect participant’s safety). Participants with isolated proteinuria resulting from MM are eligible, provided they fulfil criteria given in Table 4.
    20. Ongoing Grade 2 or higher peripheral neuropathy or neuropathic pain.
    21. Active or history of venous thromboembolism within the past 3 months.
    22. Contraindications to or unwilling to undergo protocol-required anti-thrombotic prophylaxis
    23. Current corneal disease except for mild punctuate keratopathy (Section 10.9).
    24. Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions (including lab abnormalities) that could interfere with participant’s safety, obtaining informed consent or compliance to the study procedures.
    26. Pregnant or lactating female.
    1. Leucemia plasmacellulare attiva al momento dello screening. Amiloidosi sintomatica, sindrome di POEMS (polineuropatia, organomegalia, endocrinopatia, disturbo proliferativo delle plasmacellule monoclonali e alterazioni cutanee).
    2. Partecipanti dopo pregresso SCT allogenico.
    3. Terapia sistemica antimieloma (incluse chemioterapia e steroidi sistemici) o uso di un farmaco sperimentale entro 14 giorni o cinque emivite (a seconda di quale sia più breve) precedenti la prima dose del farmaco dello studio; precedente trattamento con un farmaco basato su anticorpo monoclonale entro 30 giorni dalla somministrazione della prima dose dei farmaci dello studio.
    4. Plasmaferesi entro 7 giorni prima della prima dose del farmaco dello studio.
    5. Previo/a trattamento o intolleranza a pomalidomide.
    6. Previa terapia mirata contro BCMA.
    7. Intollerante a bortezomib o refrattario a bortezomib (ovvero, il partecipante ha manifestato una progressione della malattia durante il trattamento, oppure entro 60 giorni dal completamento del trattamento, con un regime terapeutico contenente bortezomib da 1,3 mg/m2 due volte a settimana).
    8. Evidenza di rischio cardiovascolare incluso uno qualsiasi dei seguenti:
    a. Evidenza di attuali aritmie clinicamente significative non trattate tra cui anomalie all’ECG clinicamente significative tra cui blocco atrioventricolare (AV) di 2º grado (tipo Mobitz II) o di 3º grado.
    b. Anamnesi di infarto miocardico acuto, sindromi coronariche acute (compresa angina instabile), angioplastica coronarica o stent o bypass coronarico entro 3 mesi dallo screening.
    c. Insufficienza cardiaca di classe III o IV, come definita dal sistema di classificazione funzionale della New York Heart Association (Sezione 10.8).
    d. Ipertensione non controllata.
    9. Qualsiasi intervento chirurgico maggiore entro le ultime 4 settimane.
    10. Neoplasia maligna invasiva pregressa o concomitante diversa dal mieloma multiplo, fatta eccezione per quanto segue:
    • la malattia deve essere considerata clinicamente stabile per almeno 2 anni; o
    • il partecipante non deve essere trattato con terapia attiva, a parte la terapia ormonale, per questa malattia.
    12. Evidenza di sanguinamento mucosale o interno attivo.
    13. Cirrosi o attuale malattia epatica o biliare instabile secondo la valutazione dello sperimentatore, definita dalla presenza di ascite, encefalopatia, coagulopatia, ipoalbuminemia, varici esofagee o gastriche, itterizia persistente.
    14. Infezione attiva che richiede trattamento.
    15. Nota infezione da virus dell’immunodeficienza umana (HIV).
    16. Presenza di antigene di superficie dell’epatite B (HbsAg) o anticorpo del anti-core dell’epatite B (HbcAb) allo screening o nei 3 mesi precedenti la prima dose del trattamento dello studio.
    17. Esito positivo del test per gli anticorpi dell’C o esito positivo al test dell’RNA dell’epatite C allo screening o nei 3 mesi precedenti la prima dose del trattamento dello studio.
    18. Intolleranza o controindicazioni alla profilassi antivirale.
    19. Presenza di condizioni renali attive (ad esempio infezione, grave disfunzione renale che richiede la dialisi o qualsiasi altra condizione che potrebbe influire sulla sicurezza del partecipante). I partecipanti con proteinuria isolata derivante da MM sono idonei, a condizione che soddisfino i criteri forniti nella Tabella 4.
    20. Neuropatia periferica o dolore neuropatico in corso di grado 2 o superiore
    21. Tromboembolia venosa attiva o pregressa negli ultimi 3 mesi.
    22. Controindicazioni a mancata disponibilità a sottoporsi alla profilassi antitrombotica richiesta dal protocollo
    23. Attuale malattia della cornea, fatta eccezione per una lieve cheratopatia puntata (Sezione 10.9).
    E.5 End points
    E.5.1Primary end point(s)
    Progression-free Survival (PFS), defined as the time from the date of randomization until the earliest date of documented disease progression or death due to any cause
    Sopravvivenza libera da progressione (PFS), definita come tempo dalla data di randomizzazione fino alla prima data della progressione o morte
    E.5.1.1Timepoint(s) of evaluation of this end point
    Nap
    Nap
    E.5.2Secondary end point(s)
    •Minimal Residual Disease (MRD) negativity rate, defined as the percentage of participants who are MRD negative by next-generation sequencing (NGS)
    •Overall Response Rate (ORR), defined as the percentage of participants with a confirmed partial response (PR) or better (i.e., PR, VGPR, CR, and sCR)
    •Complete Response Rate (CRR), defined as the percentage of participants with a confirmed CR or better (i.e., CR, and sCR)
    •VGPR or better rate, defined as the percentage of participants with a confirmed Very Good Partial Response (VGPR) or better (i.e., VGPR, CR, and
    sCR)
    •Duration of Response (DoR), defined as the time from first documented evidence of PR or better until progressive disease (PD) or death due to PD among participants who achieve confirmed PR or better
    •Time to Best Response (TTBR), defined as the interval of time between the date of randomization and the earliest date of achieving best response
    among participants with a confirmed PR or better
    •Time to Response (TTR), defined as the time between the date of randomization and the first documented evidence of response (PR or better)
    among participants who achieve confirmed PR or better
    •Time to Progression (TTP), defined as the time from the date of randomization until the earliest date of documented PD or death due to PD
    •Overall Survival (OS), defined as the time from the date of randomization until the date of death due to any cause
    •PFS2, defined as time from randomization to disease progression after initiation of new anti-cancer therapy or death from any cause, whichever is earlier. If disease progression after new anti-cancer therapy cannot be measured, a PFS event is defined as the date of discontinuation of new anti-cancer therapy, or death from any cause, whichever is earlier
    •Incidence of adverse events (AEs) and changes in laboratory parameters
    •Ocular findings on ophthalmic exam
    •Plasma concentrations of belantamab mafodotin, total mAb and cys-mcMMAF
    •Derived pomalidomide pharmacokinetic parameter values, as data permit
    •Incidence and titers of ADAs against belantamab mafodotin
    •Changes from baseline in symptoms and related impacts as measured by PRO-CTCAE
    •Change from baseline in HRQOL as measured by EORTC QLQ-C30, EORTC IL52 (the disease symptoms domain of the EORTC QLQ-MY20)
    Tasso di negatività per la malattia minima residua (MRD), definito come la percentuale di partecipanti risultati negativi alla MRD mediante il sequenziamento di nuova generazione (NGS)
    Tasso di risposta complessiva (ORR), definito come la percentuale di partecipanti con una risposta parziale (PR) confermata o esito migliore (ovvero PR, VGPR, CR e sCR)
    • Tasso di risposta completa (CRR), definito come la percentuale di partecipanti con CR o esito migliore (ovvero CR e sCR)
    • Tasso VGPR o esito migliore, definito come la percentuale di partecipanti con una risposta parziale molto buona (VGPR) o esito migliore (ovvero VGPR, CR e sCR)
    • Durata della risposta (DoR)
    • Tempo alla migliore risposta (TTBR)
    • Tempo alla risposta (TTR)
    • Tempo alla progressione (TTP)
    • Sopravvivenza globale (OS)
    • Sopravvivenza libera da progressione 2 (PFS2)
    Incidenza di eventi avversi (EA) e variazioni nei parametri di laboratorio
    • Riscontri oculari all’esame oftalmologico
    Concentrazioni plasmatiche di belantamab mafodotin, anticorpi monoclonali (mAb) totali e cys-mcMMAF
    Valori dei parametri di farmacocinetica derivati, come consentito dai dati
    Incidenza e titoli di ADA contro belantamab mafodotin
    Variazioni dal basale nei sintomi e relativo impatto misurato mediante PRO-CTCAE
    Variazione dal basale nella HRQOL misurata tramite EORTC QLQ-C30 e EORTC IL52 (il dominio dei sintomi della malattia di EORTC QLQ-MY20)
    E.5.2.1Timepoint(s) of evaluation of this end point
    see prot.
    vedere prot.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA42
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Canada
    Czech Republic
    France
    Germany
    Greece
    India
    Israel
    Italy
    Japan
    Korea, Republic of
    Poland
    Spain
    Turkey
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    End of study is defined as 5 years from Last Subject First Visit (LSFV), or when all participants have died, withdrawn consent or have been lost to follow-up, whichever occurs first.
    la fine dello studio è definita da 5 anni dalla LSLF, o quando tutti i artecipanti saranno deceduti, usciti dallo studio o persi al FU a seconda di quello che accadrà prima
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years6
    E.8.9.1In the Member State concerned months7
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years6
    E.8.9.2In all countries concerned by the trial months7
    E.8.9.2In all countries concerned by the trial days21
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 165
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 285
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state23
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 166
    F.4.2.2In the whole clinical trial 284
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    There is no planned provision of study intervention following the end of the study. The Investigator is responsible for ensuring that consideration has been given to the poststudy care of the participant's medical condition.
    here is no planned provision of study intervention following the end of the study. The Investigator is responsible for ensuring that consideration has been given to the poststudy care of the participant's medical condition
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2020-08-12
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2020-07-06
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA